drugset / Trial / NCT03151057
Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies
Phase 1
Terminated
16 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Gilead Sciences · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a study to evaluate the safety of idelalisib as post-transplantation maintenance in patients with B cell hematologic malignancies undergoing a allogeneic hematopoietic stem cell transplant (HSCT). Safety will be evaluated through the assessment of cytopenias, effect on donor chimerism, effect on the incidence and severity of acute graft versus host disease, and gastro-intestinal tolerance.
Timeline
- Start
- 2018-07-31
- Primary completion
- 2022-06-20
- Completion
- 2022-07-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Idelalisib | Small molecule | 100 mg | Oral |